Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Remember This Tweet

<< Previous

Bullboard Posts

Next >>

Comment by MetzGERon Oct 13, 2022 2:39am

90 Views

Post# 35021457

RE:Remember This Tweet

I bet that we won't hear about Shiseido arbitration Until Next year.
Replicel is a company which is able to Delay EVERYTHING. It is No Problem For them to delay an arbitration which should be resolved within 1 year.

maybe they Are also able to delay wars or holidays

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”